Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in Major Depressive Disorder (TERPSIS STUDY)
NCT05165394 is registered in ClinicalTrials.gov with Neurocrine Biosciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in Major Depressive Disorder (TERPSIS STUDY)
- Lead sponsor
- Neurocrine Biosciences
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 2021
- Completion date
- September 13, 2023
- Enrollment
- 93 (actual)
- Sites
- 23
Conditions
As the registry lists them; a condition with its own page is linked.